The creation of retatrutide, a novel dual agonist targeting both GLP-1 and GIP receptors, involves a complex several-stage organic process. Early routes focused on peptide portion coupling, utilizing solid-phase creation methodologies to build the long protein sequence. Subsequent study has explo